Hospitals & Health Systems
Molecular capability your own team can run
Not a vendor relationship you depend on indefinitely - a capability that stays: validated assays, deployed informatics, trained staff and a governance framework.
What we hear
What we hear from laboratory and clinical leadership
- A precision-medicine mandate, funding attached, and no operating model to execute it
- Send-out testing costs rising and turnaround times that clinicians notice
- Molecular tumour boards without the analytic support they need to be useful
- Bioinformatics staff who cannot be recruited at any realistic salary
What we do about it
One workstream, one accountable lead
We design the operating model, deploy the informatics, validate the assay menu against your case mix, train your people and hand it over. Then we support it at whatever level you want - including none.
Where we typically start
Entry points that pay for themselves first
| Entry point | Timeframe |
|---|---|
| Clinical Bioinformatics & Variant Interpretation | 8–16 weeks to deploy |
| Assay Development | 8–16 weeks per assay |
On data, privacy and residency
Health data governance is not a footnote. In-region deployment options exist, data flows are documented in every proposal, and we expect - and welcome - your information security review. Raise residency requirements at the first meeting so they are designed in rather than discovered late.
Proof
What it looks like in practice
A hospital network's molecular tumour board stood up with a validated 12-assay menu, deployed interpretation platform and trained staff across four sites. Reporting turnaround on hereditary cancer cut from 21 days to 6.
Representative programme - illustrates typical scope and outcomes; not an individual client account. Client-specific references are available on request under confidentiality.
Enterprise AI for Life Sciences
Ready to Advance Your Drug Discovery Pipeline?
Partner with Prognica Labs to leverage enterprise-grade AI, computational chemistry, and molecular simulation technologies that accelerate discovery, reduce development risk, and improve R&D productivity.
From biotech startups to global pharmaceutical organizations, we help research teams make faster, evidence-driven decisions across every stage of early drug discovery.